Vegetarian Omega Longevity Base

B87· Mostly solid

Public • 04 Feb 2026

Plant-based omega-3 support for long-term cardiometabolic health.

← Back Try alternative layout

Buy stack

Vegetarian Omega Longevity Base

longevity vegetarian cardiometabolic

Algal Omega-3 (EPA/DHA)

Daily

MODERATE

1000mg

Vitamin D3

Daily

MODERATE

50mg

No interactions detected · 1 synergy found

Each dose includes evidence rationale · doses personalized to your weight

Stack note

Private note on this stack

Track how this stack felt, what you want to change next cycle, or anything you want to save privately in your member zone.

AI risk assessment

Context: No wearable data

PROAI risk assessment is available with Pro.

See plans

Stack pre-check

No personal data connected — connect wearables or upload bloodwork for a personalised check

Clean

Supplements

Training load

Unknown

No flags

No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis

Pharmacokinetic + pair-level checks

1 synergyNo conflicts

Synergies detected

Synergy

Vitamin D3 + Omega-3: fat-soluble synergyPMID:22190928

Vitamin D3 absorption is higher when taken with fat-containing meals. Omega-3 is also best taken with meals for absorption, so co-administering them with a fat-containing meal is a practical timing synergy.

→Take both with your largest fat-containing meal of the day.

Timing optimizations

Algal Omega-3 (EPA/DHA)

With fat-containing meal

Fat-soluble. Bioavailability is significantly higher when taken with food vs fasting. (Onset: ~4h, half-life: ~72h)

Vitamin D3

With largest fat-containing meal

Fat-soluble. Co-ingestion with dietary fat increases absorption by 32–56%. (Onset: ~12h, half-life: ~360h)

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Supplements

2 items

Algal Omega-3 (EPA/DHA)Moderate

Daily •

Buy ingredient →

1000mg

DHA bioavailability from algal oil versus fish/salmon

Moderate

Population: Healthy adults aged 20–65 years

Study type: Randomized open-label parallel-group bioequivalence trial

Dose context: —

DHA levels in plasma phospholipids increased ~80% & in erythrocytes ~25% with both algal-oil capsules & cooked salmon; the two sources were bioequivalent in raising plasma & red blood cell DHA, supporting algal oil as a non-fish DHA source.

Citation: Arterburn LM, Oken HA, Bailey Hall E, et al. Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid. J Am Diet Assoc. 2008;108(7):1204-9.•DOI: 10.1016/j.jada.2008.04.020•https://pubmed.ncbi.nlm.nih.gov/18589030/

Randomized, n=32; confirms algal DHA bioequivalence to salmon-derived DHA.

Cardiovascular outcomes & mortality

Moderate

Population: General adults and cardiovascular risk populations

Study type: Systematic review and meta-analysis

Dose context: —

Omega-3 supplementation (including algal-derived DHA/EPA) associated with reductions in cardiovascular events; evidence supports algal oil as a functionally equivalent omega-3 source.

Citation: See Omega-3 cardiovascular outcome trials meta-analysis.•https://pmc.ncbi.nlm.nih.gov/articles/PMC12129820/

PMC full-text review.

Vitamin D3Moderate

Daily •

Buy ingredient →

50mg

Prevention of acute respiratory tract infections

Moderate

Population: Children and adults (ages 0–95); 25 RCTs, n=11,321

Study type: Systematic review and meta-analysis of individual participant data from RCTs

Dose context: —

Vitamin D supplementation reduced risk of acute respiratory tract infection (adjusted OR 0.88, 95% CI 0.81–0.96); greatest benefit in those with baseline deficiency (<25 nmol/L) & those receiving daily or weekly dosing rather than bolus doses.

Citation: Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583.•DOI: 10.1136/bmj.i6583•https://pubmed.ncbi.nlm.nih.gov/28202713/

IPD meta-analysis; high statistical power; effect strongest in vitamin D-deficient individuals.

Vitamin D status & physical performance in athletes

Low

Population: Competitive and recreational athletes

Study type: Narrative review

Dose context: —

Vitamin D insufficiency is prevalent among athletes, particularly indoor athletes & those in northern latitudes in winter. Insufficiency is associated with reduced muscle strength, power, & endurance; supplementation of 2,000–6,000 IU/day recommended to maintain 25(OH)D >40 ng/mL.

Citation: Yoon S, Kwon O, Kim J. Vitamin D in athletes: focus on physical performance and musculoskeletal injuries. Phys Act Nutr. 2021;25(2):20-25.•DOI: 10.20463/pan.2021.0011•https://pubmed.ncbi.nlm.nih.gov/34315203/

Narrative review; prevalence data robust, intervention evidence more limited.

Fracture prevention in elderly adults

Moderate

Population: Ambulatory and institutionalized elderly persons

Study type: Systematic review and meta-analysis of RCTs

Dose context: —

Vitamin D at 700–800 IU/day reduced hip fracture risk by 26% (RR 0.74) & any nonvertebral fracture by 23% (RR 0.77); no significant benefit was observed at 400 IU/day.

Citation: Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257-64.•DOI: 10.1001/jama.293.18.2257•https://pubmed.ncbi.nlm.nih.gov/15886381/

Dose-dependent effect; 400 IU/day insufficient for fracture prevention.